Skip to content
Awesome – Lifestyle
Author:
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions
June 9, 2026
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
April 14, 2026
Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
March 5, 2026